Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time
SaniSure, a global developer and manufacturer of single-use technology for the biopharmaceutical industry, announced today it has acquired GL Engineering (GLE) of East Hanover, New Jersey.
Cytiva’s FlexFactory is a one-stop solution for equipment and services following single-use technology and a modular design tailored to the manufacturer’s needs.
Watson-Marlow is pleased to announce that construction will start in October 2021, on a new state-of-the-art manufacturing facility in the United States, with first production due in late 2022.
MilliporeSigma today announced the opening of its second Carlsbad, California-based facility, significantly expanding its CDMO footprint.
Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines.
MicroCNX connectors are a critically important option for a range of bioprocessing, cell therapy and gene therapy workflows,.”Until now, cumbersome tube welding has been the only way to make sterile closed connections of very small-bore tubing. The MicroCNX connector represents a huge innovation for the industry.
Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces.
Cytiva, a global life sciences leader, has partnered with Mycenax Biotech Inc, a leading biopharmaceutical CDMO company, to launch Taiwan’s first continuous bioprocessing lab.
Artiva Biotherapeutics, an oncology company specializing in primary allogeneic natural killer (NK) cell therapies to treat cancer, announced on Aug. 12, 2021 an expansion of its US presence with a new R&D and GMP manufacturing facility in San Diego, Calif., for cell therapies.
As new and novel drug therapies are developed to address areas where conventional medicines are limited, drug delivery innovators, designers and manufacturers have turned to Picocyl for its unique, patented power solutions for drug and implant delivery systems.
Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
